Lingyin Li

Lingyin Li

Auto-generated profile, based on publicly available information

Lingyin Li

Department of Biochemistry, Stanford University; Stanford, CA 94305, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Cell
Verified
Journal Article
Closed access
SESabrina L. Ergun
Sabrina L. Ergun
DFDaniel Fernandez
Daniel Fernandez
TWThomas M. Weiss
Thomas M. Weiss
LLLingyin Li
Lingyin Li

24 February 2020 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
JCJacqueline A. Carozza
Jacqueline A. Carozza
VBVolker Böhnert
Volker Böhnert
KNKhanh C. Nguyen
Khanh C. Nguyen
GSGemini Skariah
Gemini Skariah
KSKelsey E. Shaw
Kelsey E. Shaw
LLLingyin Li
Lingyin Li

1 July 2019 in Molecular Cell
Verified
Journal Article
Closed access
CRChristopher Ritchie
Christopher Ritchie
ACAnthony F. Cordova
Anthony F. Cordova
GHGaelen T. Hess
Gaelen T. Hess
MBMichael C. Bassik
Michael C. Bassik
LLLingyin Li
Lingyin Li

1 November 2020 in Molecular Cell
Verified
Journal Article
Closed access
LLLauren J. Lahey
Lauren J. Lahey
RMRachel E. Mardjuki
Rachel E. Mardjuki
XWXianlan Wen
Xianlan Wen
GHGaelen T. Hess
Gaelen T. Hess
CRChristopher Ritchie
Christopher Ritchie
LLLingyin Li
Lingyin Li

7 June 2021 in ACS Central Science
Verified
Journal Article
Open access
ACAnthony F. Cordova
Anthony F. Cordova
CRChristopher Ritchie
Christopher Ritchie
VBVolker Böhnert
Volker Böhnert
LLLingyin Li
Lingyin Li
Administration of exogenous CDNs to activate the cGAMP-STING pathway is a promising therapeutic strategy to unleash the full potential of cancer immunotherapy. This strategy mirrors the role of endogenous extracellular cGAMP, an immunotransmitter that is transferred from cancer cells to cGAMP-sensing cells in the host, promoting immunity. However, the CDN import mechanisms used by host cells within tumors remain unknown. Here we identified the protein SLC46A2 as the dominant cGAMP importer in primary human monocytes. Furthermore, we discovered that monocytes and M1-polarized macrophages directly sense tumor-derived extracellular cGAMP in murine tumors. Finally, we demonstrated that SLC46A2 is the dominant cGAMP importer in monocyte-derived macrophages. Together, we provide the first cellular and molecular mechanisms of cGAMP as an immunotransmitter, paving the way for effective STING pathway therapeutics.

21 June 2022 in Annual Review of Biochemistry
Verified
Journal Article
Closed access
CRChristopher Ritchie
Christopher Ritchie
JCJacqueline A. Carozza
Jacqueline A. Carozza
LLLingyin Li
Lingyin Li
In the decade since the discovery of the innate immune cyclic GMP–AMP synthase (cGAS)–2′3′-cyclic GMP–AMP (cGAMP)–stimulator of interferon genes (STING) pathway, its proper activation and dysregulation have been rapidly implicated in many aspects of human disease. Understanding the biochemical, cellular, and regulatory mechanisms of this pathway is critical to developing therapeutic strategies that either harness it to boost defense or inhibit it to prevent unwanted inflammation. In this review, we first discuss how the second messenger cGAMP is synthesized by cGAS in response to double-stranded DNA and cGAMP's subsequent activation of cell-type-dependent STING signaling cascades with differential physiological consequences. We then review how cGAMP as an immunotransmitter mediates tightly controlled cell–cell communication by being exported from producing cells and imported into responding cells via cell-type-specific transporters. Finally, we review mechanisms by which thecGAS–cGAMP–STING pathway responds to different sources of mislocalized double-stranded DNA in pathogen defense, cancer, and autoimmune diseases.